CYTK
Price
$34.66
Change
+$0.30 (+0.87%)
Updated
Jul 3 closing price
Capitalization
4.14B
25 days until earnings call
NGENF
Price
$2.45
Change
+$0.03 (+1.24%)
Updated
Jul 3 closing price
Capitalization
183.96M
Interact to see
Advertisement

CYTK vs NGENF

Header iconCYTK vs NGENF Comparison
Open Charts CYTK vs NGENFBanner chart's image
Cytokinetics
Price$34.66
Change+$0.30 (+0.87%)
Volume$1.3M
Capitalization4.14B
NervGen Pharma
Price$2.45
Change+$0.03 (+1.24%)
Volume$55.06K
Capitalization183.96M
CYTK vs NGENF Comparison Chart in %
Loading...
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NGENF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CYTK vs. NGENF commentary
Jul 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYTK is a StrongBuy and NGENF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 06, 2025
Stock price -- (CYTK: $34.66 vs. NGENF: $2.45)
Brand notoriety: CYTK and NGENF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYTK: 71% vs. NGENF: 26%
Market capitalization -- CYTK: $4.14B vs. NGENF: $183.96M
CYTK [@Biotechnology] is valued at $4.14B. NGENF’s [@Biotechnology] market capitalization is $183.96M. The market cap for tickers in the [@Biotechnology] industry ranges from $310.37B to $0. The average market capitalization across the [@Biotechnology] industry is $2.38B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYTK’s FA Score shows that 1 FA rating(s) are green whileNGENF’s FA Score has 0 green FA rating(s).

  • CYTK’s FA Score: 1 green, 4 red.
  • NGENF’s FA Score: 0 green, 5 red.
According to our system of comparison, CYTK is a better buy in the long-term than NGENF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYTK’s TA Score shows that 4 TA indicator(s) are bullish while NGENF’s TA Score has 3 bullish TA indicator(s).

  • CYTK’s TA Score: 4 bullish, 3 bearish.
  • NGENF’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, CYTK is a better buy in the short-term than NGENF.

Price Growth

CYTK (@Biotechnology) experienced а +2.21% price change this week, while NGENF (@Biotechnology) price change was -9.55% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.93%. For the same industry, the average monthly price growth was +17.38%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

CYTK is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+6.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CYTK($4.14B) has a higher market cap than NGENF($184M). NGENF YTD gains are higher at: 12.568 vs. CYTK (-26.318). NGENF has higher annual earnings (EBITDA): -25.94M vs. CYTK (-513.62M). CYTK has more cash in the bank: 938M vs. NGENF (14.6M). NGENF has less debt than CYTK: NGENF (81.8K) vs CYTK (791M). CYTK has higher revenues than NGENF: CYTK (19.2M) vs NGENF (0).
CYTKNGENFCYTK / NGENF
Capitalization4.14B184M2,249%
EBITDA-513.62M-25.94M1,980%
Gain YTD-26.31812.568-209%
P/E RatioN/AN/A-
Revenue19.2M0-
Total Cash938M14.6M6,425%
Total Debt791M81.8K966,993%
FUNDAMENTALS RATINGS
CYTK vs NGENF: Fundamental Ratings
CYTK
NGENF
OUTLOOK RATING
1..100
5079
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
96
Overvalued
PROFIT vs RISK RATING
1..100
8381
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
6345
P/E GROWTH RATING
1..100
1100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NGENF's Valuation (96) in the null industry is in the same range as CYTK (100) in the Biotechnology industry. This means that NGENF’s stock grew similarly to CYTK’s over the last 12 months.

NGENF's Profit vs Risk Rating (81) in the null industry is in the same range as CYTK (83) in the Biotechnology industry. This means that NGENF’s stock grew similarly to CYTK’s over the last 12 months.

NGENF's SMR Rating (100) in the null industry is in the same range as CYTK (100) in the Biotechnology industry. This means that NGENF’s stock grew similarly to CYTK’s over the last 12 months.

NGENF's Price Growth Rating (45) in the null industry is in the same range as CYTK (63) in the Biotechnology industry. This means that NGENF’s stock grew similarly to CYTK’s over the last 12 months.

CYTK's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for NGENF (100) in the null industry. This means that CYTK’s stock grew significantly faster than NGENF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CYTKNGENF
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
88%
Momentum
ODDS (%)
Bullish Trend 3 days ago
77%
Bearish Trend 3 days ago
76%
MACD
ODDS (%)
N/A
Bearish Trend 3 days ago
86%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
74%
Bearish Trend 3 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
75%
Bearish Trend 3 days ago
84%
Advances
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 10 days ago
82%
Declines
ODDS (%)
Bearish Trend 6 days ago
78%
Bearish Trend 4 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
83%
N/A
Aroon
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 4 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NGENF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
WDSCX17.890.17
+0.96%
Allspring SMID Cap Growth Fund - Cl C
FWBTX14.760.08
+0.54%
Fidelity Advisor Multi-Asset Income C
TLVAX24.100.10
+0.42%
Timothy Plan Large/Mid Cap Value A
RGGHX39.760.15
+0.38%
American Funds Global Balanced R2E
DHPAX17.820.05
+0.28%
Diamond Hill Mid Cap Inv

NGENF and

Correlation & Price change

A.I.dvisor tells us that NGENF and CYTK have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NGENF and CYTK's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NGENF
1D Price
Change %
NGENF100%
+1.40%
CYTK - NGENF
25%
Poorly correlated
+0.87%
IBRX - NGENF
23%
Poorly correlated
+3.03%
TNFA - NGENF
22%
Poorly correlated
+2.07%
CARM - NGENF
22%
Poorly correlated
-4.05%
ATRA - NGENF
22%
Poorly correlated
+2.61%
More